A5007474183- Pregnancy and Medication Impact
- Urinary Bladder and Prostate Research
- Pregnancy and preeclampsia studies
- Pain Mechanisms and Treatments
- Maternal Mental Health During Pregnancy and Postpartum
- Pharmacology and Obesity Treatment
- Pharmacological Effects and Toxicity Studies
- Reproductive System and Pregnancy
- Sexual function and dysfunction studies
- Hormonal and reproductive studies
- Hernia repair and management
- Chemotherapy-induced organ toxicity mitigation
- Neurotransmitter Receptor Influence on Behavior
- Bone and Joint Diseases
- Prenatal Substance Exposure Effects
- Bone health and treatments
- Phytochemistry and Biological Activities
- Abdominal Surgery and Complications
- Electrolyte and hormonal disorders
- Neonatal Health and Biochemistry
- Humor Studies and Applications
- Pregnancy-related medical research
- Cardiac and Coronary Surgery Techniques
- Pharmacological Effects of Natural Compounds
- Folate and B Vitamins Research
Karadeniz Technical University
2016-2025
University Hospital of Lausanne
2016
Institute of Social and Preventive Medicine
2016
Royal Hospital for Women
2015
Aims TNF‐α inhibitors are considered relatively safe in pregnancy but experience is still limited. The aim of this study was to evaluate the risk major birth defects, spontaneous abortion, preterm and reduced weight after first trimester exposure inhibitors. Methods Pregnancy outcomes women on adalimumab, infliximab, etanercept, certolizumab pegol or golimumab were evaluated a prospective observational cohort compared with non‐exposed random sample. samples drawn from pregnancies identified...
To investigate pregnancy outcomes following maternal use of pregabalin.This multicenter, observational prospective cohort study compared in women exposed to pregabalin with those matched controls (not any medications known be teratogenic or antiepileptic drugs). Teratology Information Services systematically collected data between 2004 and 2013.Data were from 164 pregnancies 656 controls. A significantly higher major birth defect rate the group was observed after exclusion chromosomal...
Aims Metformin is used to treat type 2 diabetes, polycystic ovary syndrome associated infertility, and gestational diabetes. This study aims evaluate the safety of metformin in early pregnancy. Method We evaluated risk major birth defects pregnancy losses a cohort pregnant women exposed during first trimester for different indications relative matched unexposed reference group. Results The was 5.1% (20/392) pregnancies 2.1% (9/431) group [adjusted odds ratio (OR) 1.70; 95% CI 0.70–4.38]....
This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy of 63 and 62 interferon-β-exposed pregnancies were compared. Rates major congenital anomalies (MCA) 4.8% (2/42) in the group versus 2.3% (1/44) interferon-β (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio spontaneous abortion was 0.6 (95% 0.2–1.8). Further studies are needed to definitely rule out a moderately...
Objective: We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and combination nitric oxide synthase (nOS) inhibitors.Materials Methods: Twenty-four male Sprague Dawley (12 weeks old, weighing 262±18 g) were randomly assigned into 4 groups (n=6).Group I was control group.In Group II, intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks.In III, received weekly ip 30 L-nAME (nonspecific nOS inhibitor) min before IV, L-nIL (inducible weeks.Rats...
We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and combination nitric oxide synthase (NOS) inhibitors.Twenty-four male Sprague Dawley (12 weeks old, weighing 262±18 g) were randomly assigned into 4 groups (n=6). Group I was control group. In II, intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks. III, received weekly ip 30 L-NAME (nonspecific NOS inhibitor) min before IV, L-NIL (inducible Rats weighed 2 times week. At end 6 weeks, hearts...